Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Germany's Merz under fire in Brazil for his comments on Amazon host city of COP30 - 2What is the Insurrection Act? Can Trump really use the military to 'put an end' to Minneapolis ICE protests?
- 3Outer space conditions hamper sperm's ability to navigate toward an egg
- 44 Coolers for Present day Kitchens
- 5Hezbollah uses ambulances, paramedic uniforms, as disguise for terrorist activity, IDF says
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- The Force of Systems administration: Individual Examples of overcoming adversity
- New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
- Instructions to Grasp the Innovation Behind 5G Pinnacles\
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- Apollo vs. Artemis: What to know about NASA's return to the moon
- Ukraine proved this drone-killer works. Now, the West is giving it a shot.
- Bomb blast in packed Nigerian mosque kills five
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
